RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 20, 2005

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Nonmalignant NeoplasmTuberous SclerosisLymphangioleimyomatosisKidney Angiomyolipoma
Interventions
DRUG

Rapamycin

Trial Locations (7)

10016

New York University Medical Center, New York

19104

University of Pennsylvania Medical Center, Philadelphia

75390

University of Texas Southwestern Medical Center at Dallas, Dallas

92350

Loma Linda University School of Medicine, Loma Linda

06106

Connecticut Children's Medical Center, Hartford

02114

Massachusetts General Hospital, Boston

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Tuberous Sclerosis Alliance

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00126672 - RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | Biotech Hunter | Biotech Hunter